US Stock Insider Trading | Fulgent Genetics disclosed 16 insider trading transactions on February 25

K-LinePoet · 2026-03-15T21:33:27+00:00

On February 25, 2026, Fulgent Genetics disclosed multiple insider transactions, primarily involving stock sales by executives and shareholders holding more than 10% of the company. The transactions involved relatively significant quantities and amounts, reflecting company dynamics. Fulgent Genetics is a technology company focused on genetic diagnostics and cancer treatment research and development.

K-LinePoet

2026-03-15 21:33:27

Abstract generation in progress

On February 25, 2026, Fulgent Genetics (FLGT) disclosed 16 insider transactions. Shareholder Hsieh Ming, who owns more than 10%, sold 31,800 shares on February 24, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 25, 2026	Executive	Xie Jian	February 23, 2026	Sell	655	23.01	15,100
February 25, 2026	Executive	Xie Jian	February 24, 2026	Sell	26,200	23.09	604,200
February 25, 2026	Executive	Gao Hanlin	February 24, 2026	Sell	15,300	23.09	353,300
February 25, 2026	Executive	Kim Paul	February 23, 2026	Sell	661	23.01	15,200
February 25, 2026	Executive	Gao Hanlin	February 23, 2026	Sell	403	23.01	9,273
February 25, 2026	Shareholder with >10% stake	Hsieh Ming	February 24, 2026	Sell	63,300	23.09	1,462,600
February 25, 2026	Shareholder with >10% stake	Hsieh Ming	February 23, 2026	Sell	2,167	23.01	49,900
February 25, 2026	Executive	Kim Paul	February 24, 2026	Sell	26,800	23.09	618,600
January 28, 2026	Executive	Kim Paul	January 26, 2026	Sell	3,004	27.53	82,700
January 28, 2026	Executive	Gao Hanlin	January 26, 2026	Sell	1,331	27.53	36,600

【Company Profile】

Fulgent Genetics, Inc. was incorporated in Delaware, USA, on May 13, 2016. The company is a technology-driven enterprise with established clinical diagnostics and therapeutic development businesses. Its clinical diagnostics division offers molecular diagnostic testing, comprehensive genetic testing, and high-quality anatomic pathology laboratory services aimed at providing clinically actionable diagnostic information to doctors and patients to improve patient care. The therapeutic development division focuses on developing candidate drugs for various cancers using novel nanocapsulation and targeted therapy platforms, designed to improve the therapeutic window and pharmacokinetic (PK) profiles of new and existing cancer drugs. The company’s goal is to transform from a genomic diagnostics business into a fully integrated precision medicine company.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes